PPB - Services

Complaints, Feedback and Enquiry

๐€๐๐ฏ๐š๐ง๐œ๐ข๐ง๐  ๐‡๐ž๐š๐ฅ๐ญ๐ก ๐๐ซ๐จ๐๐ฎ๐œ๐ญ ๐‘๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐ข๐จ๐ง๐ฌ: ๐๐๐ ๐„๐ง๐ ๐š๐ ๐ž๐ฌ ๐ฐ๐ข๐ญ๐ก ๐Š๐€๐๐ˆ ๐š๐ง๐ ๐Œ๐„๐ƒ๐€๐Š ๐’๐ญ๐š๐ค๐ž๐ก๐จ๐ฅ๐๐ž๐ซ๐ฌ – 27th March 2024

Nairobi, Kenya – Today, the Pharmacy and Poisons Board (PPB) met with representatives from the Kenya Association of Pharmaceutical Industry (KAPI) and the Medical Technology Industry Association of Kenya (MEDAK) to address pivotal challenges and progressions within the pharmaceutical and medical device sectors.

During the meeting, both parties committed to fostering collaboration to fortify regulatory frameworks, ensuring access to top-tier, secure, and efficient health products and technologies (HPTs).

Leading the PPB delegation was Chief Executive Officer PPB was represented by Chief Executive Officer Dr. F.M. Siyoi, while Dr. James Mukoro represented KAPI and Mr. Steve Kipkoti MEDAK respectively.

Author

Public Relations

Leave a comment

Your email address will not be published. Required fields are marked *